土耳其的先天性蔗糖异麦芽糖酶缺乏症;单个中心的经验。

IF 1.6 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Scandinavian Journal of Gastroenterology Pub Date : 2024-06-01 Epub Date: 2024-03-08 DOI:10.1080/00365521.2024.2324961
Doğan Barut, Ezgi Kıran Taşcı, Bora Kunay, Burcu Güven, Betül Aksoy, Yeliz Çağan Appak, Miray Karakoyun, Funda Çetin, Ayşe Selimoğlu, Huseyin Onay, Sema Aydoğdu
{"title":"土耳其的先天性蔗糖异麦芽糖酶缺乏症;单个中心的经验。","authors":"Doğan Barut, Ezgi Kıran Taşcı, Bora Kunay, Burcu Güven, Betül Aksoy, Yeliz Çağan Appak, Miray Karakoyun, Funda Çetin, Ayşe Selimoğlu, Huseyin Onay, Sema Aydoğdu","doi":"10.1080/00365521.2024.2324961","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Congenital sucrase-isomaltase deficiency (CSID) is a rare inherited carbohydrate malabsorption disorder caused by <i>sucrase-isomaltase</i> (<i>SI</i>) gene variants. In CSID, an autosomal recessively inherited disease, symptoms can also be seen in individuals with heterozygous mutations.</p><p><strong>Methods: </strong>The variant spectrum was evaluated retrospectively in individuals who presented with chronic diarrhea between 2014 and 2022 and had undergone genetic testing of the <i>SI</i> gene considering CSID due to diet-related complaints.</p><p><strong>Results: </strong>Ten patients with chronic diarrhea were genetically evaluated with <i>SI</i> gene sequencing. In patients diagnosed with CSID and whose symptoms improved with enzyme replacement therapy, the genetic mutation zygosity was found to be heterozygous at a rate of 90%. In 10% of the patients, the mutation was homozygous. Limiting consuming sucrose and isomaltose foods reduced the patients' complaints, but the symptoms did not disappear completely. With the initiation of sacrosidase enzyme replacement therapy, the patient's complaints completely disappeared.</p><p><strong>Conclusion: </strong>In CSID, defined as an autosomal recessive disease, clinical symptoms can also be seen in heterozygous cases previously described as carriers, and these patients also benefit from sacrosidase enzyme replacement therapy. In light of these findings, the autosomal recessive definition of CSID does not fully characterize the disease.What is Known:CSID is a rare inherited carbohydrate malabsorption disorder caused by <i>sucrase-isomaltase</i> gene variants.In congenital sucrase-isomaltase deficiency, an autosomal recessively inherited disorder, symptoms can also be seen in individuals with heterozygous mutations.What is new:Severe disease symptoms can also be seen in heterozygous cases, which were thought to be carriers because the disease was previously described as autosomal recessive.Sacrosidase enzyme replacement therapy also eliminates the disease symptoms in patients with heterozygous CSID mutations.<b>This is the second study on sucrase-isomaltase enzyme deficiency pediatric groups in Türkiye and Europe.</b></p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Congenital sucrase-isomaltase deficiency in Türkiye; a single center experience.\",\"authors\":\"Doğan Barut, Ezgi Kıran Taşcı, Bora Kunay, Burcu Güven, Betül Aksoy, Yeliz Çağan Appak, Miray Karakoyun, Funda Çetin, Ayşe Selimoğlu, Huseyin Onay, Sema Aydoğdu\",\"doi\":\"10.1080/00365521.2024.2324961\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Congenital sucrase-isomaltase deficiency (CSID) is a rare inherited carbohydrate malabsorption disorder caused by <i>sucrase-isomaltase</i> (<i>SI</i>) gene variants. In CSID, an autosomal recessively inherited disease, symptoms can also be seen in individuals with heterozygous mutations.</p><p><strong>Methods: </strong>The variant spectrum was evaluated retrospectively in individuals who presented with chronic diarrhea between 2014 and 2022 and had undergone genetic testing of the <i>SI</i> gene considering CSID due to diet-related complaints.</p><p><strong>Results: </strong>Ten patients with chronic diarrhea were genetically evaluated with <i>SI</i> gene sequencing. In patients diagnosed with CSID and whose symptoms improved with enzyme replacement therapy, the genetic mutation zygosity was found to be heterozygous at a rate of 90%. In 10% of the patients, the mutation was homozygous. Limiting consuming sucrose and isomaltose foods reduced the patients' complaints, but the symptoms did not disappear completely. With the initiation of sacrosidase enzyme replacement therapy, the patient's complaints completely disappeared.</p><p><strong>Conclusion: </strong>In CSID, defined as an autosomal recessive disease, clinical symptoms can also be seen in heterozygous cases previously described as carriers, and these patients also benefit from sacrosidase enzyme replacement therapy. In light of these findings, the autosomal recessive definition of CSID does not fully characterize the disease.What is Known:CSID is a rare inherited carbohydrate malabsorption disorder caused by <i>sucrase-isomaltase</i> gene variants.In congenital sucrase-isomaltase deficiency, an autosomal recessively inherited disorder, symptoms can also be seen in individuals with heterozygous mutations.What is new:Severe disease symptoms can also be seen in heterozygous cases, which were thought to be carriers because the disease was previously described as autosomal recessive.Sacrosidase enzyme replacement therapy also eliminates the disease symptoms in patients with heterozygous CSID mutations.<b>This is the second study on sucrase-isomaltase enzyme deficiency pediatric groups in Türkiye and Europe.</b></p>\",\"PeriodicalId\":21461,\"journal\":{\"name\":\"Scandinavian Journal of Gastroenterology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/00365521.2024.2324961\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00365521.2024.2324961","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:先天性蔗糖异麦芽糖酶缺乏症(CSID)是一种罕见的遗传性碳水化合物吸收不良疾病,由蔗糖异麦芽糖酶(SI)基因变异引起。CSID 是一种常染色体隐性遗传疾病,杂合突变个体也可出现症状:方法:对2014年至2022年期间出现慢性腹泻,并因饮食相关主诉而接受SI基因检测以考虑CSID的患者进行变异谱回顾性评估:对10名慢性腹泻患者进行了SI基因测序遗传学评估。在被确诊为 CSID 并接受酶替代疗法后症状有所改善的患者中,发现基因突变杂合率为 90%。10%的患者基因突变为同型。限制食用蔗糖和异麦芽糖食物减轻了患者的不适,但症状并未完全消失。在开始使用蔗糖酶替代治疗后,患者的症状完全消失:结论:CSID 被定义为常染色体隐性遗传病,在以前被描述为携带者的杂合子病例中也可出现临床症状,这些患者也可从蔗糖酶替代疗法中获益。已知病例:CSID是一种罕见的遗传性碳水化合物吸收不良症,由蔗糖酶-异麦芽糖酶基因变异引起。先天性蔗糖酶-异麦芽糖酶缺乏症是一种常染色体隐性遗传疾病,杂合子突变个体也可出现症状。新发现:在杂合子病例中也可出现严重的疾病症状,由于该病以前被描述为常染色体隐性遗传病,因此被认为是携带者。蔗糖酶酶替代疗法也可消除杂合子CSID突变患者的疾病症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Congenital sucrase-isomaltase deficiency in Türkiye; a single center experience.

Background: Congenital sucrase-isomaltase deficiency (CSID) is a rare inherited carbohydrate malabsorption disorder caused by sucrase-isomaltase (SI) gene variants. In CSID, an autosomal recessively inherited disease, symptoms can also be seen in individuals with heterozygous mutations.

Methods: The variant spectrum was evaluated retrospectively in individuals who presented with chronic diarrhea between 2014 and 2022 and had undergone genetic testing of the SI gene considering CSID due to diet-related complaints.

Results: Ten patients with chronic diarrhea were genetically evaluated with SI gene sequencing. In patients diagnosed with CSID and whose symptoms improved with enzyme replacement therapy, the genetic mutation zygosity was found to be heterozygous at a rate of 90%. In 10% of the patients, the mutation was homozygous. Limiting consuming sucrose and isomaltose foods reduced the patients' complaints, but the symptoms did not disappear completely. With the initiation of sacrosidase enzyme replacement therapy, the patient's complaints completely disappeared.

Conclusion: In CSID, defined as an autosomal recessive disease, clinical symptoms can also be seen in heterozygous cases previously described as carriers, and these patients also benefit from sacrosidase enzyme replacement therapy. In light of these findings, the autosomal recessive definition of CSID does not fully characterize the disease.What is Known:CSID is a rare inherited carbohydrate malabsorption disorder caused by sucrase-isomaltase gene variants.In congenital sucrase-isomaltase deficiency, an autosomal recessively inherited disorder, symptoms can also be seen in individuals with heterozygous mutations.What is new:Severe disease symptoms can also be seen in heterozygous cases, which were thought to be carriers because the disease was previously described as autosomal recessive.Sacrosidase enzyme replacement therapy also eliminates the disease symptoms in patients with heterozygous CSID mutations.This is the second study on sucrase-isomaltase enzyme deficiency pediatric groups in Türkiye and Europe.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
5.30%
发文量
222
审稿时长
3-8 weeks
期刊介绍: The Scandinavian Journal of Gastroenterology is one of the most important journals for international medical research in gastroenterology and hepatology with international contributors, Editorial Board, and distribution
期刊最新文献
Mitotic spindle positioning protein serves as prognostic biomarker in patients with colorectal cancer. Mortality and rate of hospitalization stratified by patients' BMI in a colonoscopy screening - a cross sectional analysis of data from Polish Colonoscopy Screening Platform. The impact of anal incontinence: psychosocial and sexual consequences and factors associated with QoL in a Norwegian outpatient population. EndoFLIP evaluation of the pylorus during minimal invasive Ivor-Levis esophagectomy. Estrogen receptor beta (ERβ) in esophageal cancer - a systematic review and meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1